menu
    • menu
    [{"orgOrder":0,"company":"Prague Scientific","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CZECH REPUBLIC","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Omeprazole Magnesium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Prague Scientific","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Prague Scientific \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Prague Scientific \/ Undisclosed"},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Omeprazole Magnesium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Perrigo Company plc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Perrigo Company plc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Perrigo Company plc \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Gaelan Medical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Omeprazole Magnesium","moa":"||Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Gaelan Medical","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Gaelan Medical"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Omeprazole Magnesium","moa":"||Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Omeprazole Magnesium","moa":"||Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Omeprazole Magnesium","moa":"||Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Phil","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Omeprazole Magnesium","moa":"||Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Phil","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Phil"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Omeprazole Magnesium","moa":"||Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Cosmo Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Cosmo Pharmaceuticals"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Entera Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Termination","leadProduct":"Omeprazole Magnesium","moa":"||Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Entera Health","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Entera Health"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"HealthCare Royalty Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Financing","leadProduct":"Omeprazole Magnesium","moa":"||Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ HealthCare Royalty Partners","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ HealthCare Royalty Partners"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Omeprazole Magnesium","moa":"||Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Omeprazole Magnesium","moa":"||Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Omeprazole Magnesium","moa":"||Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Omeprazole Magnesium","moa":"||Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Omeprazole Magnesium","moa":"||Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"Omeprazole Magnesium","moa":"||Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Omeprazole Magnesium

    Menu

    Omeprazole Magnesium

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            RedHill Biopharma

                            Israel arrow
                            OTS 2025
                            Not Confirmed

                            RedHill Biopharma

                            Israel arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : $1.8 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            RedHill Biopharma inks $1.8 million Middle East licensing deal for Talicia

                            Details : Through the licensing deal for Omeprazole Magnesium, targeting Potassium-transporting ATPase, the focus is on addressing Helicobacter pylori (H. pylori) infection.

                            Product Name : Talicia

                            Product Type : Miscellaneous

                            Upfront Cash : $0.2 million

                            October 08, 2025

                            Lead Product(s) : Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : $1.8 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            RedHill Biopharma

                            Israel arrow
                            OTS 2025
                            Not Confirmed

                            RedHill Biopharma

                            Israel arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation

                            Details : Talicia is a novel, fixed-dose combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (omeprazole), approved by the U.S. FDA for the treatment of H. pylori infection.

                            Product Name : Talicia

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 18, 2025

                            Lead Product(s) : Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            RedHill Biopharma

                            Israel arrow
                            OTS 2025
                            Not Confirmed

                            RedHill Biopharma

                            Israel arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Omeprazole Magnesium,Omeprazole,Rifabutin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Talicia® Launched in the United Arab Emirates

                            Details : Talicia is a novel, fixed-dose combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (omeprazole), approved by the U.S. FDA for the treatment of H. pylori infection.

                            Product Name : Talicia

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 21, 2024

                            Lead Product(s) : Omeprazole Magnesium,Omeprazole,Rifabutin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            RedHill Biopharma

                            Israel arrow
                            OTS 2025
                            Not Confirmed

                            RedHill Biopharma

                            Israel arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Omeprazole Magnesium,Omeprazole,Rifabutin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Runni...

                            Details : Talicia is a novel, fixed-dose, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (PPI) (omeprazole), approved by the U.S. FDA for the treatment of H. pylori infection in adults.

                            Product Name : Talicia

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 27, 2023

                            Lead Product(s) : Omeprazole Magnesium,Omeprazole,Rifabutin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            RedHill Biopharma

                            Israel arrow
                            OTS 2025
                            Not Confirmed

                            RedHill Biopharma

                            Israel arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            RedHill Announces FDA sNDA Approval for Talicia®

                            Details : Talicia is a novel, fixed-dose, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (PPI) (omeprazole), approved by the U.S. FDA for the treatment of H. pylori infection in adults.

                            Product Name : Talicia

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 18, 2023

                            Lead Product(s) : Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            RedHill Biopharma

                            Israel arrow
                            OTS 2025
                            Not Confirmed

                            RedHill Biopharma

                            Israel arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            RedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First Commercial Order Outside th...

                            Details : Talicia (omeprazole magnesium, amoxicillin and rifabutin) is a novel, fixed-dose, all-in-one oral capsule combination of two antibiotics and a proton pump inhibitor (PPI) (omeprazole), used for the treatment of H. pylori infection.

                            Product Name : Talicia

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 01, 2023

                            Lead Product(s) : Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            RedHill Biopharma

                            Israel arrow
                            OTS 2025
                            Not Confirmed

                            RedHill Biopharma

                            Israel arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Phil

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Phil and RedHill Biopharma Partner to Increase Access to Talicia®

                            Details : Under the agreement, RedHill will make Talicia, a novel, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (omeprazole magnesium), approved for H. pylori infection, available via the PhilRx Pat...

                            Product Name : Talicia

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            July 06, 2023

                            Lead Product(s) : Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Phil

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Prague Scientific

                            Czech Republic arrow
                            OTS 2025
                            Not Confirmed

                            Prague Scientific

                            Czech Republic arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Omeprazole Magnesium

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Zent2U Announces Successful Pivotal Bioequivalence Study Results on Omeprazole Immediate Release Capsules

                            Details : Omeprazole magnesium is a proton-pump inhibitor, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid...

                            Product Name : Omeprazole Magnesium-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 25, 2022

                            Lead Product(s) : Omeprazole Magnesium

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Perrigo Company plc

                            Ireland arrow
                            OTS 2025
                            Not Confirmed

                            Perrigo Company plc

                            Ireland arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Omeprazole Magnesium

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Perrigo Announces U.S. FDA Approval For Omeprazole Magnesium Delayed-Release Mini Capsules

                            Details : Omeprazole Magnesium Delayed-Release Mini Capsules, 20 mg over-the-counter (OTC),represents a first-to-market mini capsule form of omeprazole, which is indicated for treatment of frequent heartburn.

                            Product Name : Omeprazole Magnesium-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 26, 2022

                            Lead Product(s) : Omeprazole Magnesium

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            RedHill Biopharma

                            Israel arrow
                            OTS 2025
                            Not Confirmed

                            RedHill Biopharma

                            Israel arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            RedHill Presents New Talicia® Data Analyses at DDW 2022

                            Details : Talicia (Omeprazole Magnesium) efficacy and safety profile evaluated in patients with H. pylori infection and diabetes mellitus, a large and challenging patient population associated with sub-optimal outcomes with clarithromycin-based H. pylori eradicati...

                            Product Name : Talicia

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 25, 2022

                            Lead Product(s) : Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth